Biomarkers and outcomes for pembrolizumab/axitinib for kidney cancer
In this phase 1b study, he researchers were looking for [...]
Circulating tumour DNA as a potential prognostic biomarker for immunotherapy
A study published in Nature Cancer showed that blood levels [...]
Safety and efficacy of nivolumab for non-clear cell kidney cancer
Nivolumab alone and in combination with ipilimumab is used for the treatment of [...]
Comparison of first-line immunotherapy combinations for metastatic kidney cancer
This meta-analysis of first-line immunotherapy trials was published in the [...]
Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors
This retrospective study published in the Journal of Clinical Oncology [...]
Sunitinib re-challenge in patients with metastatic kidney cancer
A study published in Clinical Genitourinary Cancer looks at the [...]
Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab
In a paper published in Clinical Genitourinary Cancer the link [...]
Bone metastases are associated with poor prognosis in papillary kidney cancer
A recent retrospective study looked at the data from 49 [...]
ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC
Results from a phase II study of bevacizumab and erlotinib [...]
ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer
Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]
